Logo image of EYPT

EYEPOINT PHARMACEUTICALS INC (EYPT) Stock Fundamental Analysis

NASDAQ:EYPT - Nasdaq - US30233G2093 - Common Stock - Currency: USD

10.17  -0.19 (-1.83%)

After market: 10.6 +0.43 (+4.23%)

Fundamental Rating

4

EYPT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While EYPT has a great health rating, there are worries on its profitability. While showing a medium growth rate, EYPT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year EYPT has reported negative net income.
In the past year EYPT has reported a negative cash flow from operations.
EYPT had negative earnings in each of the past 5 years.
EYPT had negative operating cash flow in 4 of the past 5 years.
EYPT Yearly Net Income VS EBIT VS OCF VS FCFEYPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -40.48%, EYPT is in line with its industry, outperforming 44.04% of the companies in the same industry.
EYPT has a Return On Equity (-49.19%) which is in line with its industry peers.
Industry RankSector Rank
ROA -40.48%
ROE -49.19%
ROIC N/A
ROA(3y)-35.96%
ROA(5y)-35.91%
ROE(3y)-57.18%
ROE(5y)-89.71%
ROIC(3y)N/A
ROIC(5y)N/A
EYPT Yearly ROA, ROE, ROICEYPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

Looking at the Gross Margin, with a value of 93.29%, EYPT belongs to the top of the industry, outperforming 96.89% of the companies in the same industry.
EYPT's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for EYPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.5%
GM growth 5Y1.04%
EYPT Yearly Profit, Operating, Gross MarginsEYPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

7

2. Health

2.1 Basic Checks

EYPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EYPT has more shares outstanding
Compared to 5 years ago, EYPT has more shares outstanding
There is no outstanding debt for EYPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EYPT Yearly Shares OutstandingEYPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
EYPT Yearly Total Debt VS Total AssetsEYPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

EYPT has an Altman-Z score of 2.75. This is not the best score and indicates that EYPT is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.75, EYPT is in the better half of the industry, outperforming 70.47% of the companies in the same industry.
There is no outstanding debt for EYPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.75
ROIC/WACCN/A
WACC9.9%
EYPT Yearly LT Debt VS Equity VS FCFEYPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

EYPT has a Current Ratio of 7.85. This indicates that EYPT is financially healthy and has no problem in meeting its short term obligations.
EYPT has a better Current ratio (7.85) than 78.24% of its industry peers.
EYPT has a Quick Ratio of 7.79. This indicates that EYPT is financially healthy and has no problem in meeting its short term obligations.
EYPT's Quick ratio of 7.79 is fine compared to the rest of the industry. EYPT outperforms 78.76% of its industry peers.
Industry RankSector Rank
Current Ratio 7.85
Quick Ratio 7.79
EYPT Yearly Current Assets VS Current LiabilitesEYPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for EYPT have decreased strongly by -32.42% in the last year.
Looking at the last year, EYPT shows a quite strong growth in Revenue. The Revenue has grown by 12.03% in the last year.
The Revenue has been growing by 16.26% on average over the past years. This is quite good.
EPS 1Y (TTM)-32.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
Revenue 1Y (TTM)12.03%
Revenue growth 3Y5.42%
Revenue growth 5Y16.26%
Sales Q2Q%109.29%

3.2 Future

Based on estimates for the next years, EYPT will show a very strong growth in Earnings Per Share. The EPS will grow by 21.17% on average per year.
The Revenue is expected to grow by 62.75% on average over the next years. This is a very strong growth
EPS Next Y-29.18%
EPS Next 2Y-14.24%
EPS Next 3Y-7.37%
EPS Next 5Y21.17%
Revenue Next Year-5.38%
Revenue Next 2Y-35.9%
Revenue Next 3Y25.37%
Revenue Next 5Y62.75%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
EYPT Yearly Revenue VS EstimatesEYPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
EYPT Yearly EPS VS EstimatesEYPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EYPT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EYPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EYPT Price Earnings VS Forward Price EarningsEYPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EYPT Per share dataEYPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as EYPT's earnings are expected to decrease with -7.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.24%
EPS Next 3Y-7.37%

More info and screens

0

5. Dividend

5.1 Amount

EYPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EYEPOINT PHARMACEUTICALS INC

NASDAQ:EYPT (7/14/2025, 8:00:02 PM)

After market: 10.6 +0.43 (+4.23%)

10.17

-0.19 (-1.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)07-30 2025-07-30
Inst Owners104.83%
Inst Owner Change0%
Ins Owners3.57%
Ins Owner Change0%
Market Cap699.80M
Analysts85.26
Price Target32.22 (216.81%)
Short Float %10.64%
Short Ratio8.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.19%
Min EPS beat(2)-25.16%
Max EPS beat(2)2.78%
EPS beat(4)2
Avg EPS beat(4)-6.45%
Min EPS beat(4)-25.16%
Max EPS beat(4)4.9%
EPS beat(8)4
Avg EPS beat(8)-23.12%
EPS beat(12)7
Avg EPS beat(12)-18.18%
EPS beat(16)9
Avg EPS beat(16)-15.16%
Revenue beat(2)2
Avg Revenue beat(2)101.47%
Min Revenue beat(2)2.42%
Max Revenue beat(2)200.52%
Revenue beat(4)3
Avg Revenue beat(4)50.55%
Min Revenue beat(4)-3.15%
Max Revenue beat(4)200.52%
Revenue beat(8)6
Avg Revenue beat(8)35.83%
Revenue beat(12)8
Avg Revenue beat(12)23.65%
Revenue beat(16)9
Avg Revenue beat(16)17.4%
PT rev (1m)0%
PT rev (3m)-4.29%
EPS NQ rev (1m)-0.14%
EPS NQ rev (3m)-18.45%
EPS NY rev (1m)0.05%
EPS NY rev (3m)-6.62%
Revenue NQ rev (1m)-1.86%
Revenue NQ rev (3m)-4.63%
Revenue NY rev (1m)-0.9%
Revenue NY rev (3m)64.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.49
P/FCF N/A
P/OCF N/A
P/B 2.35
P/tB 2.35
EV/EBITDA N/A
EPS(TTM)-2.41
EYN/A
EPS(NY)-3.01
Fwd EYN/A
FCF(TTM)-2.2
FCFYN/A
OCF(TTM)-2.15
OCFYN/A
SpS0.81
BVpS4.34
TBVpS4.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.48%
ROE -49.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.29%
FCFM N/A
ROA(3y)-35.96%
ROA(5y)-35.91%
ROE(3y)-57.18%
ROE(5y)-89.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.5%
GM growth 5Y1.04%
F-Score4
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 180.74%
Cap/Sales 5.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.85
Quick Ratio 7.79
Altman-Z 2.75
F-Score4
WACC9.9%
ROIC/WACCN/A
Cap/Depr(3y)367.17%
Cap/Depr(5y)224.18%
Cap/Sales(3y)7.38%
Cap/Sales(5y)4.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-32.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
EPS Next Y-29.18%
EPS Next 2Y-14.24%
EPS Next 3Y-7.37%
EPS Next 5Y21.17%
Revenue 1Y (TTM)12.03%
Revenue growth 3Y5.42%
Revenue growth 5Y16.26%
Sales Q2Q%109.29%
Revenue Next Year-5.38%
Revenue Next 2Y-35.9%
Revenue Next 3Y25.37%
Revenue Next 5Y62.75%
EBIT growth 1Y-85.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year296.07%
EBIT Next 3Y52.44%
EBIT Next 5YN/A
FCF growth 1Y-135.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-140.19%
OCF growth 3YN/A
OCF growth 5YN/A